Omnes Capital's investments

The company specialises in monetising and marketing cross-platform video games that run on mobiles, tablets, Facebook or web browsers. The company has built up a substantial portfolio of games, including the highly popular Hero Zero by developer Playata. Hero Zero has signed up more than 17 million users and ranked as the eighth most searched-for game in Brazil during 2013, coming in ahead of AAA titles such as PES 2014.

Greenbureau is the first free-of-charge confidential and secure internet service that centralises bills for consumers. A pioneer of multi-brand digital customer relationships, Greenbureau saves on running costs for large groups by switching their customers over to digital billing, invoicing and online account management, etc.

Mister Bell joind the Tree Digital Factory Group.

Mister Bell is a mobile performance based mobile advertising network founded in 2010.
With an exclusive inventory and unprecedented distribution capacity, Mister Bell is establishing itself as one of the leaders in mobile performance in Europe, Latin America and the Middle East. With its proprietary advertising tracking and re-targeting systems on smartphones and tablets, Mister Bell guarantees ROI levels to advertisers and offers innovative monetisation systems to content providers. Mister Bell is headquartered in Paris and now has subsidiaries in London, Berlin and Rio.

Progexia is an alternative operator serving private health insurance companies, wich provide solutions in the Cloud for reduce benefits payments costs.

Pixium Vision was founded in December 2011 by Bernard Gilly, Professor José-Alain Sahel, and several highly renowned scientists from prestigious academic and technology institutions. The company develops innovative vision restoration systems (VRS) that are active medical devices. They can be implanted to treat blindness caused by degeneration of the photo-receptor cells of the retina. VRS stimulate the retina to produce a bionic vision and aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Called IRIS® (in clinical trials) and PRIMA (under development), these VRS harness the latest advances in microelectronics/nanoelectronics, optronics, neurobiology and software. With the help of these technologies, Pixium Vision ultimately aims to provide a therapeutic solution delivering bionic vision as close as possible to normal vision.